Liu X, et al. - This trial was designed in order to examine the importance of epidermal growth factor receptor (EGFR) expression in molecular apocrine breast cancer (MABC). In order to determine the prognosis of patients with MABC, the identification of new targets such as epidermal growth factor receptor 2 (HER2) and EGFR could be useful. It was reported that the utility of both androgen receptor (AR) and EGFR as therapeutic targets could be particularly vital in MABC, and could serve as a guide to opt for suitable treatments in the case of individual breast cancer patients.